Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

Abstract Background Janus kinase inhibitors (JAKi) are new targeted synthetic disease-modifying antirheumatic drugs (DMARDs) licenced in the UK to treat rheumatoid and psoriatic arthritides. Unlike currently often prescribed biological DMARDs, they target a different part of the inflammatory pathway...

Full description

Bibliographic Details
Main Authors: Savia de Souza, Ruth Williams, Elena Nikiphorou
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Rheumatology
Subjects:
JAK inhibitors
Clinical practice
Patient perspective
Inflammatory arthritis
Rheumatoid arthritis
Psoriatic arthritis
Online Access:https://doi.org/10.1186/s41927-023-00370-7

Internet

https://doi.org/10.1186/s41927-023-00370-7

Similar Items